ReviewVaccine2011
Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines.
Review in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Clinical, immunohistochemical, and pathological assessment of a mouse model of experimental autoimmune encephalomyelitis induced by a eukaryotic RpfE-MOGMolecular biology reports · 2026Article
- Insights and challenges on animal models for progressive multiple sclerosis.Journal of neuroinflammation · 2026Review
- Preparation and In vitro/In vivo Evaluation of Fingolimod hydrochloride Loaded Polymeric Mixed Nano-Micelles for Treatment of Multiple Sclerosis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Zebrafish as a Model for Multiple Sclerosis.Biomedicines · 2024Review
- Identifying and reducing risks of neurological complications associated with vaccination.Nature reviews. Neurology · 2024Review
- Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis.Brain sciences · 2020Review
- Rodent Models of Optic Neuritis.Frontiers in neurology · 2020Review
- The miRNA Expression Profile of Experimental Autoimmune Encephalomyelitis Reveals Novel Potential Disease Biomarkers.International journal of molecular sciences · 2018Article
- A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4Frontiers in immunology · 2018Article
- Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.Clinical reviews in allergy & immunology · 2017Review
- Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis.Autoimmunity · 2015Article
- A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model.Alzheimer's research & therapy · 2014Article
- Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.PloS one · 2014Article
- Multiple sclerosis: autoimmunity and viruses.Current opinion in rheumatology · 2013Review
- Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation.Nature medicine · 2013Article
- DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration.International journal of clinical and experimental medicine · 2012Article
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).British journal of pharmacology · 2011Review
- Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.Annals of neurology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for EAE can occur as a result of either live viral infection or DNA immunization with molecular mimics of CNS proteins or peptides. Here we review the published data describing modulation of EAE through administration of various CNS proteins/peptides introduced via live virus or plasmid DNA and modulation of EAE through choice of adjuvant (immunostimulating agents).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.